Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study
Metastasectomy and/or local ablative therapy in metastatic colorectal cancer (mCRC) patients often provide long-term survival. Health-related quality of life (HRQoL) data in curatively treated mCRC are limited. In the RAXO-study that evaluated repeated resectability, a multi-cross-sectional HRQoL su...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/7/1713 |
| _version_ | 1797440162867707904 |
|---|---|
| author | Kaisa Lehtomäki Hanna P. Stedt Emerik Osterlund Timo Muhonen Leena-Maija Soveri Päivi Halonen Tapio K. Salminen Juha Kononen Raija Kallio Annika Ålgars Eetu Heervä Annamarja Lamminmäki Aki Uutela Arno Nordin Juho Lehto Tiina Saarto Harri Sintonen Pirkko-Liisa Kellokumpu-Lehtinen Raija Ristamäki Bengt Glimelius Helena Isoniemi Pia Osterlund |
| author_facet | Kaisa Lehtomäki Hanna P. Stedt Emerik Osterlund Timo Muhonen Leena-Maija Soveri Päivi Halonen Tapio K. Salminen Juha Kononen Raija Kallio Annika Ålgars Eetu Heervä Annamarja Lamminmäki Aki Uutela Arno Nordin Juho Lehto Tiina Saarto Harri Sintonen Pirkko-Liisa Kellokumpu-Lehtinen Raija Ristamäki Bengt Glimelius Helena Isoniemi Pia Osterlund |
| author_sort | Kaisa Lehtomäki |
| collection | DOAJ |
| description | Metastasectomy and/or local ablative therapy in metastatic colorectal cancer (mCRC) patients often provide long-term survival. Health-related quality of life (HRQoL) data in curatively treated mCRC are limited. In the RAXO-study that evaluated repeated resectability, a multi-cross-sectional HRQoL substudy with 15D, EQ-5D-3L, QLQ-C30, and QLQ-CR29 questionnaires was conducted. Mean values of patients in different treatment groups were compared with age- and gender-standardized general Finnish populations. The questionnaire completion rate was 444/477 patients (93%, 1751 questionnaires). Mean HRQoL was 0.89–0.91 with the 15D, 0.85–0.87 with the EQ-5D, 68–80 with the EQ-5D-VAS, and 68–79 for global health status during curative treatment phases, with improvements in the remission phase (disease-free >18 months). In the remission phase, mean EQ-5D and 15D scores were similar to the general population. HRQoL remained stable during first- to later-line treatments, when the aim was no longer cure, and declined notably when tumour-controlling therapy was no longer meaningful. The symptom burden affecting mCRC survivors’ well-being included insomnia, impotence, urinary frequency, and fatigue. Symptom burden was lower after treatment and slightly higher, though stable, through all phases of systemic therapy. HRQoL was high in curative treatment phases, further emphasizing the strategy of metastasectomy in mCRC when clinically meaningful. |
| first_indexed | 2024-03-09T12:04:07Z |
| format | Article |
| id | doaj.art-d900a7fbd0dc4bd5a7e43b7645583820 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T12:04:07Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d900a7fbd0dc4bd5a7e43b76455838202023-11-30T23:01:00ZengMDPI AGCancers2072-66942022-03-01147171310.3390/cancers14071713Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-StudyKaisa Lehtomäki0Hanna P. Stedt1Emerik Osterlund2Timo Muhonen3Leena-Maija Soveri4Päivi Halonen5Tapio K. Salminen6Juha Kononen7Raija Kallio8Annika Ålgars9Eetu Heervä10Annamarja Lamminmäki11Aki Uutela12Arno Nordin13Juho Lehto14Tiina Saarto15Harri Sintonen16Pirkko-Liisa Kellokumpu-Lehtinen17Raija Ristamäki18Bengt Glimelius19Helena Isoniemi20Pia Osterlund21Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön Katu 34, 33520 Tampere, FinlandDepartment of Oncology, Kuopio University Hospital, Puijonlaaksontie 2, 70210 Kuopio, FinlandDepartment of Immunology, Genetics and Pathology, Uppsala University, Rudbecklaboratoriet, Dag Hammarskjölds Väg 20, 75185 Uppsala, SwedenDepartment of Oncology, South Carelia Central Hospital, Valto Käkelän Katu 1, 53130 Lappeenranta, FinlandHome Care, Joint Municipal Authority for Health Care and Social Services in Keski-Uusimaa, Sairaalakatu 1, 05850 Hyvinkää, FinlandDepartment of Oncology, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, FinlandFaculty of Medicine and Health Technology, Tampere University, Arvo Ylpön Katu 34, 33520 Tampere, FinlandDepartment of Oncology, Central Finland Central Hospital, Keskussairaalantie 19, 40620 Jyväskylä, FinlandDepartment of Oncology, Oulu University Hospital, Kajaanintie 50, 90220 Oulu, FinlandDepartment of Oncology, Turku University Hospital, Hämeentie 11, 20520 Turku, FinlandDepartment of Oncology, Turku University Hospital, Hämeentie 11, 20520 Turku, FinlandDepartment of Oncology, Kuopio University Hospital, Puijonlaaksontie 2, 70210 Kuopio, FinlandDepartment of Transplantation and Liver Surgery, Abdominal Centre, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, FinlandDepartment of Transplantation and Liver Surgery, Abdominal Centre, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, FinlandFaculty of Medicine and Health Technology, Tampere University, Arvo Ylpön Katu 34, 33520 Tampere, FinlandDepartment of Oncology, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, FinlandDepartment of Public Health, University of Helsinki, Tukholmankatu 8B, 00290 Helsinki, FinlandFaculty of Medicine and Health Technology, Tampere University, Arvo Ylpön Katu 34, 33520 Tampere, FinlandDepartment of Oncology, Turku University Hospital, Hämeentie 11, 20520 Turku, FinlandDepartment of Immunology, Genetics and Pathology, Uppsala University, Rudbecklaboratoriet, Dag Hammarskjölds Väg 20, 75185 Uppsala, SwedenDepartment of Transplantation and Liver Surgery, Abdominal Centre, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, FinlandFaculty of Medicine and Health Technology, Tampere University, Arvo Ylpön Katu 34, 33520 Tampere, FinlandMetastasectomy and/or local ablative therapy in metastatic colorectal cancer (mCRC) patients often provide long-term survival. Health-related quality of life (HRQoL) data in curatively treated mCRC are limited. In the RAXO-study that evaluated repeated resectability, a multi-cross-sectional HRQoL substudy with 15D, EQ-5D-3L, QLQ-C30, and QLQ-CR29 questionnaires was conducted. Mean values of patients in different treatment groups were compared with age- and gender-standardized general Finnish populations. The questionnaire completion rate was 444/477 patients (93%, 1751 questionnaires). Mean HRQoL was 0.89–0.91 with the 15D, 0.85–0.87 with the EQ-5D, 68–80 with the EQ-5D-VAS, and 68–79 for global health status during curative treatment phases, with improvements in the remission phase (disease-free >18 months). In the remission phase, mean EQ-5D and 15D scores were similar to the general population. HRQoL remained stable during first- to later-line treatments, when the aim was no longer cure, and declined notably when tumour-controlling therapy was no longer meaningful. The symptom burden affecting mCRC survivors’ well-being included insomnia, impotence, urinary frequency, and fatigue. Symptom burden was lower after treatment and slightly higher, though stable, through all phases of systemic therapy. HRQoL was high in curative treatment phases, further emphasizing the strategy of metastasectomy in mCRC when clinically meaningful.https://www.mdpi.com/2072-6694/14/7/1713metastatic colorectal cancermetastasectomylocal ablative therapyhealth-related quality of lifeQLQ-C30EQ-5D |
| spellingShingle | Kaisa Lehtomäki Hanna P. Stedt Emerik Osterlund Timo Muhonen Leena-Maija Soveri Päivi Halonen Tapio K. Salminen Juha Kononen Raija Kallio Annika Ålgars Eetu Heervä Annamarja Lamminmäki Aki Uutela Arno Nordin Juho Lehto Tiina Saarto Harri Sintonen Pirkko-Liisa Kellokumpu-Lehtinen Raija Ristamäki Bengt Glimelius Helena Isoniemi Pia Osterlund Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study Cancers metastatic colorectal cancer metastasectomy local ablative therapy health-related quality of life QLQ-C30 EQ-5D |
| title | Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study |
| title_full | Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study |
| title_fullStr | Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study |
| title_full_unstemmed | Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study |
| title_short | Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study |
| title_sort | health related quality of life in metastatic colorectal cancer patients treated with curative resection and or local ablative therapy or systemic therapy in the finnish raxo study |
| topic | metastatic colorectal cancer metastasectomy local ablative therapy health-related quality of life QLQ-C30 EQ-5D |
| url | https://www.mdpi.com/2072-6694/14/7/1713 |
| work_keys_str_mv | AT kaisalehtomaki healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT hannapstedt healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT emerikosterlund healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT timomuhonen healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT leenamaijasoveri healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT paivihalonen healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT tapioksalminen healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT juhakononen healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT raijakallio healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT annikaalgars healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT eetuheerva healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT annamarjalamminmaki healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT akiuutela healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT arnonordin healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT juholehto healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT tiinasaarto healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT harrisintonen healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT pirkkoliisakellokumpulehtinen healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT raijaristamaki healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT bengtglimelius healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT helenaisoniemi healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy AT piaosterlund healthrelatedqualityoflifeinmetastaticcolorectalcancerpatientstreatedwithcurativeresectionandorlocalablativetherapyorsystemictherapyinthefinnishraxostudy |